SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (434)1/9/2009 10:45:50 PM
From: ghmm   of 508
 
They CC stopping the actimmune IPF trial but that was Phase 3. Don't recall a CC for the actimmune GRACES (Ovarian Cancer) that was Phase 3 too.

EDIT: I just rechecked the INSPIRE failure call was actually mid March to announce restructuring and the like so the call wasn't to announce results they were released a few weeks earlier.

I don't see how the trial can fail. At worst the data is mediocre perhaps there is a surprise with something (the INFORM study, animal tox issue, etc.) but I think they just want to get it out.

My guess is the data is a bit better then what Telapervir has shown but nothing to make people go crazy. And Yeah I've wondered if the day are good after an initial pop if it will start being sold again. Just want to get Pirfenidone data out and move on with life :).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News